9.A.19 The Lipid Intermediate Transporter (Arv1) Family

Glycosylphosphatidylinositol (GPI), covalently attached to many eukaryotic proteins, not only acts as a membrane anchor but is also thought to be a sorting signal for GPI-anchored proteins that are associated with sphingolipid and sterol-enriched domains. GPI anchors contain a conserved core structure. The core structure is synthesized in two topologically distinct stages on the leaflets of the endoplasmic reticulum (ER). Early GPI intermediates are assembled on the cytoplasmic side of the ER and then are flipped into the ER lumen where a complete GPI precursor is synthesized and transferred to protein. The flipping process is predicted to be mediated by a flippase. Yeast Arv1p is required for the delivery of an early GPI intermediate, GlcN-acylPI, to the first mannosyltransferase of GPI synthesis in the ER lumen (Kajiwara et al., 2008). ARV1 deletion, and mutations in other proteins involved in GPI anchor synthesis, affect inositol phosphorylceramide synthesis as well as the intracellular distribution and amounts of sterols, suggesting a role of GPI anchor synthesis in lipid flow from the ER.

ER membrane cholesterol is maintained at an optimal concentration of ∼5 mol % by the net impact of sterol synthesis, modification, and export. Arv1p in S. cerevisiae is a key component of this homeostasis due to its probable role in intracellular sterol transport (Tong et al., 2010). Mammalian ARV1, which can fully complement the yeast lesion, encodes a ubiquitously expressed, resident ER protein. Repeated dosing of specific antisense oligonucleotides to ARV1 produced a marked reduction of ARV1 transcripts in liver, adipose, and to a lesser extent, intestine. This resulted in marked hypercholesterolemia, elevated serum bile acids, and activation of the hepatic farnesoid X receptor (FXR) regulatory pathway. Knockdown of ARV1 in murine liver and HepG2 cells was associated with accumulation of cholesterol in the ER at the expense of the plasma membrane and suppression of sterol regulatory element-binding proteins and their targets (Tong et al., 2010). Arv1 knockout mice exhibited a dramatic lean phenotype, with major reductions in white adipose tissue mass and body weight. This loss was accompanied by improved glucose tolerance, higher adiponectin levels, increased energy expenditure and greater rates of whole-body fatty acid oxidation (Lagor et al. 2015).

The ARV1-encoded protein mediates sterol transport from the endoplasmic reticulum (ER) to the plasma membrane. Yeast ARV1 mutants accumulate multiple lipids in the ER and are sensitive to pharmacological modulators of both sterol and sphingolipid metabolism. Shechtman et al. (2011) demonstrated sterol accumulation, subcellular membrane expansion, elevated lipid droplet formation, and vacuolar fragmentation in ARV1 mutants. Loss of subcellular lipid transport due to ARV1 deficiency disrupts organelle homeostasis and activates the unfolded protein response.  Arv1 might regulate membrane insertion of tail-anchored proteins involved in membrane homoeostasis (Georgiev et al. 2013). ACAT-related enzyme 2 required for viability 1 (ARV1) encodes a transmembrane lipid transporter in the ER, which is presented in all eukaryotes including plants. Deficiency in ARV1 is clinically presented as autosomal recessive developmental and epileptic encephalopathy 38 (DEE38) in humans and in mice (Karabinos et al. 2022). Developmental delay, intellectual disability, seizures, walking and speech impairments, as well as with a dilated cardiomyopathy (DCM) are all symptoms.

In S. cerevisiae, ARV1 encodes a 321 amino acid transmembrane protein localized to the ER and Golgi. Arv1 cells harbor defects in sphingolipid and glycosylphosphatidylinositol biosyntheses, and may harbor sterol trafficking defects. Villasmil and Nickels (2011) determined the orientation of full-length Arv1 in the ER membrane. Although 4-6 TMSs are predicted, they concluded that the protein has a 3TMS topology. They also determined the minimal protein length required for function. Arv1 has putative lipid and glycosylphosphatidylinositol intermediate transport activities. It contains a conserved N-terminal cytosolic zinc ribbon motif known as the ARV1 homology domain, followed by multiple transmembrane regions, anchoring it in the ER. Deletion of ARV1 in yeast results in defective sterol trafficking, aberrant lipid synthesis, ER stress, membrane disorganization and hypersensitivity to fatty acids (FAs).


 

References:

Georgiev, A.G., J. Johansen, V.D. Ramanathan, Y.Y. Sere, C.T. Beh, and A.K. Menon. (2013). Arv1 regulates PM and ER membrane structure and homeostasis but is dispensable for intracellular sterol transport. Traffic 14: 912-921.

Kajiwara, K., R. Watanabe, H. Pichler, K. Ihara, S. Murakami, H. Riezman, and K. Funato. (2008). Yeast ARV1 is required for efficient delivery of an early GPI intermediate to the first mannosyltransferase during GPI assembly and controls lipid flow from the endoplasmic reticulum. Mol. Biol. Cell 19: 2069-2082.

Karabinos, A., M. Hyblova, M. Eckertova, E. Tomkova, D. Schwartzova, N. Luckanicova, G. Magyarova, and G. Minarik. (2022). Dilated cardiomyopathy is a part of the ARV1-associated phenotype: a case report. J Med Case Rep 16: 98.

Lagor, W.R., F. Tong, K.E. Jarrett, W. Lin, D.M. Conlon, M. Smith, M.Y. Wang, B.O. Yenilmez, M.G. McCoy, D.W. Fields, S.M. O''Neill, R. Gupta, A. Kumaravel, V. Redon, R.S. Ahima, S.L. Sturley, J.T. Billheimer, and D.J. Rader. (2015). Deletion of murine Arv1 results in a lean phenotype with increased energy expenditure. Nutr Diabetes 5: e181.

Shechtman, C.F., A.L. Henneberry, T.A. Seimon, A.H. Tinkelenberg, L.J. Wilcox, E. Lee, M. Fazlollahi, A.B. Munkacsi, H.J. Bussemaker, I. Tabas, and S.L. Sturley. (2011). Loss of subcellular lipid transport due to ARV1 deficiency disrupts organelle homeostasis and activates the unfolded protein response. J. Biol. Chem. 286: 11951-11959.

Swain, E., J. Stukey, V. McDonough, M. Germann, Y. Liu, S.L. Sturley, and J.T. Nickels, Jr. (2002). Yeast cells lacking the ARV1 gene harbor defects in sphingolipid metabolism. Complementation by human ARV1. J. Biol. Chem. 277: 36152-36160.

Tinkelenberg, A.H., Y. Liu, F. Alcantara, S. Khan, Z. Guo, M. Bard, and S.L. Sturley. (2000). Mutations in yeast ARV1 alter intracellular sterol distribution and are complemented by human ARV1. J. Biol. Chem. 275: 40667-40670.

Tong, F., J. Billheimer, C.F. Shechtman, Y. Liu, R. Crooke, M. Graham, D.E. Cohen, S.L. Sturley, and D.J. Rader. (2010). Decreased expression of ARV1 results in cholesterol retention in the endoplasmic reticulum and abnormal bile acid metabolism. J. Biol. Chem. 285: 33632-33641.

Villasmil, M.L. and J.T. Nickels, Jr. (2011). Determination of the membrane topology of Arv1 and the requirement of the ER luminal region for Arv1 function in Saccharomyces cerevisiae. FEMS Yeast Res 11: 524-527.

Villasmil, M.L., A. Ansbach, and J.T. Nickels, Jr. (2011). The putative lipid transporter, Arv1, is required for activating pheromone-induced MAP kinase signaling in Saccharomyces cerevisiae. Genetics 187: 455-465.

Examples:

TC#NameOrganismal TypeExample
9.A.19.1.1

Lipid and glycosyl phosphatidylinositol intermediate transporter, Arv1 (Villasmil et al., 2011).

Yeast

Arv1 of Saccharomyces cerevisiae (Q06541)

 
9.A.19.1.2

Lipid intermediate transporter, Arv1 or pSLC.ARV1, of 271 aas and 4 - 6 TMSs. It plays a role as a mediator of ER cholesterol and bile acid homeostasis (Tinkelenberg et al. 2000, Swain et al. 2002) and participates in sterol transport out of the ER and distribution into plasma membranes (Tong et al. 2010). Defects in the arv1 gene give rise to developmental delay, intellectual disability, seizures, walking and speech impairments, as well as with a dilated cardiomyopathy (DCM) (Karabinos et al. 2022).

Animals

Arv1 of Homo sapiens (Q9H2C2)

 
9.A.19.1.3

Arv1-domain-containing protein of 333 aas and up to 5 TMSs.

Arv1 domain protein of Cortinarius glaucopus

 
9.A.19.1.4

Protein ARV1 of 595 aas and 6 TMSs in a 2 (N-terminal + 4 (C-terminal) TMS arrangement.

ARV1 of Plasmodium ovale

 
9.A.19.1.5

Uncharacterized protein of 224 aas and 5 TMSs in a 2 + 2 + 1 TMS arrangement.

UP of Rhododendron griersonianum

 
9.A.19.1.7

Uncharacterized protein of 256 aas and 7 TMSs in an apparent 3 + 1 + 3 TMS arrangement.

UP of Phytophthora kernoviae

 
9.A.19.1.8

Uncharacterized protein of 292 aas and 6 TMSs in a 2 + 4 TMS arrangement 

UP of Naegleria lovaniensis

 
Examples:

TC#NameOrganismal TypeExample
9.A.19.2.1

FAD-dependent oxidoreductase of 871 aas and up to 8 TMSs.

Oxidoreductase of Aspergillus indologenus